Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study.
- DOI
- 10.1007/s12325-026-03781-3
- Published
- 2026 Sep 24
- Container
- Advances in therapy
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12325-026-03781-3,
title = {Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study.},
author = {Huang CS and Dzagnidze G and Grohmann-Izay B and Liu LC and Llinás-Quintero N and Lin AN and Mishra AK and Pominchuk D and Prokharau A and Rapoport BL and Semiglazov V and Tseng LM and Ruiz EY and Loibl S},
year = {2026},
journal = {Advances in therapy},
doi = {10.1007/s12325-026-03781-3},
url = {https://doi.org/10.1007/s12325-026-03781-3}
}RIS
TY - JOUR TI - Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study. AU - Huang CS AU - Dzagnidze G AU - Grohmann-Izay B AU - Liu LC AU - Llinás-Quintero N AU - Lin AN AU - Mishra AK AU - Pominchuk D AU - Prokharau A AU - Rapoport BL AU - Semiglazov V AU - Tseng LM AU - Ruiz EY AU - Loibl S PY - 2026 JO - Advances in therapy DO - 10.1007/s12325-026-03781-3 UR - https://doi.org/10.1007/s12325-026-03781-3 ER -
APA
CS, H., G, D., B, G., LC, L., N, L., AN, L., AK, M., D, P., A, P., BL, R., V, S., LM, T., EY, R., & S, L. (2026). Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study.. Advances in therapy. https://doi.org/10.1007/s12325-026-03781-3
Source records
- pubmed · retrieved 2026-09-25T10:06:45.314Z